nodes	percent_of_prediction	percent_of_DWPC	metapath
Lithium—GRIA3—nerve—peripheral nervous system neoplasm	0.0233	0.283	CbGeAlD
Lithium—GSK3B—nerve—peripheral nervous system neoplasm	0.0202	0.245	CbGeAlD
Lithium—IMPA2—Teniposide—Etoposide—peripheral nervous system neoplasm	0.0123	1	CbGdCrCtD
Lithium—IMPA2—parotid gland—peripheral nervous system neoplasm	0.00942	0.114	CbGeAlD
Lithium—GSK3A—trigeminal ganglion—peripheral nervous system neoplasm	0.00852	0.103	CbGeAlD
Lithium—GSK3A—parotid gland—peripheral nervous system neoplasm	0.00803	0.0975	CbGeAlD
Lithium—GRIA3—cerebellum—peripheral nervous system neoplasm	0.00494	0.0599	CbGeAlD
Lithium—GSK3B—cerebellum—peripheral nervous system neoplasm	0.00427	0.0519	CbGeAlD
Lithium—GSK3A—cerebellum—peripheral nervous system neoplasm	0.00372	0.0451	CbGeAlD
Lithium—Fatigue—Melphalan—peripheral nervous system neoplasm	0.000647	0.00152	CcSEcCtD
Lithium—Coma—Epirubicin—peripheral nervous system neoplasm	0.000646	0.00152	CcSEcCtD
Lithium—Tinnitus—Cisplatin—peripheral nervous system neoplasm	0.000644	0.00152	CcSEcCtD
Lithium—Discomfort—Dactinomycin—peripheral nervous system neoplasm	0.000641	0.00151	CcSEcCtD
Lithium—Salivary hypersecretion—Doxorubicin—peripheral nervous system neoplasm	0.000635	0.00149	CcSEcCtD
Lithium—Syncope—Alitretinoin—peripheral nervous system neoplasm	0.000633	0.00149	CcSEcCtD
Lithium—Feeling abnormal—Topotecan—peripheral nervous system neoplasm	0.000632	0.00149	CcSEcCtD
Lithium—Gastrointestinal pain—Topotecan—peripheral nervous system neoplasm	0.000627	0.00148	CcSEcCtD
Lithium—Feeling abnormal—Tretinoin—peripheral nervous system neoplasm	0.000627	0.00147	CcSEcCtD
Lithium—Feeling abnormal—Isotretinoin—peripheral nervous system neoplasm	0.000627	0.00147	CcSEcCtD
Lithium—Agitation—Vincristine—peripheral nervous system neoplasm	0.000625	0.00147	CcSEcCtD
Lithium—Gastrointestinal pain—Isotretinoin—peripheral nervous system neoplasm	0.000622	0.00146	CcSEcCtD
Lithium—Gastrointestinal pain—Tretinoin—peripheral nervous system neoplasm	0.000622	0.00146	CcSEcCtD
Lithium—Oedema—Dactinomycin—peripheral nervous system neoplasm	0.000622	0.00146	CcSEcCtD
Lithium—Loss of consciousness—Alitretinoin—peripheral nervous system neoplasm	0.000621	0.00146	CcSEcCtD
Lithium—Hypertonia—Epirubicin—peripheral nervous system neoplasm	0.00062	0.00146	CcSEcCtD
Lithium—Arrhythmia—Cisplatin—peripheral nervous system neoplasm	0.000617	0.00145	CcSEcCtD
Lithium—Convulsion—Alitretinoin—peripheral nervous system neoplasm	0.000612	0.00144	CcSEcCtD
Lithium—Vertigo—Vincristine—peripheral nervous system neoplasm	0.000611	0.00144	CcSEcCtD
Lithium—Alopecia—Cisplatin—peripheral nervous system neoplasm	0.000611	0.00144	CcSEcCtD
Lithium—Abdominal pain—Topotecan—peripheral nervous system neoplasm	0.000606	0.00143	CcSEcCtD
Lithium—Body temperature increased—Topotecan—peripheral nervous system neoplasm	0.000606	0.00143	CcSEcCtD
Lithium—Arthralgia—Alitretinoin—peripheral nervous system neoplasm	0.000601	0.00141	CcSEcCtD
Lithium—Abdominal pain—Tretinoin—peripheral nervous system neoplasm	0.000601	0.00141	CcSEcCtD
Lithium—Body temperature increased—Tretinoin—peripheral nervous system neoplasm	0.000601	0.00141	CcSEcCtD
Lithium—Body temperature increased—Isotretinoin—peripheral nervous system neoplasm	0.000601	0.00141	CcSEcCtD
Lithium—Abdominal pain—Isotretinoin—peripheral nervous system neoplasm	0.000601	0.00141	CcSEcCtD
Lithium—Coma—Doxorubicin—peripheral nervous system neoplasm	0.000598	0.00141	CcSEcCtD
Lithium—Discomfort—Alitretinoin—peripheral nervous system neoplasm	0.000594	0.0014	CcSEcCtD
Lithium—Flatulence—Cisplatin—peripheral nervous system neoplasm	0.000593	0.0014	CcSEcCtD
Lithium—Anorexia—Dactinomycin—peripheral nervous system neoplasm	0.000592	0.00139	CcSEcCtD
Lithium—Convulsion—Vincristine—peripheral nervous system neoplasm	0.00059	0.00139	CcSEcCtD
Lithium—Dry mouth—Alitretinoin—peripheral nervous system neoplasm	0.000588	0.00138	CcSEcCtD
Lithium—Confusional state—Alitretinoin—peripheral nervous system neoplasm	0.000581	0.00137	CcSEcCtD
Lithium—Oedema—Alitretinoin—peripheral nervous system neoplasm	0.000576	0.00136	CcSEcCtD
Lithium—Hypertonia—Doxorubicin—peripheral nervous system neoplasm	0.000573	0.00135	CcSEcCtD
Lithium—Vision blurred—Cisplatin—peripheral nervous system neoplasm	0.000567	0.00133	CcSEcCtD
Lithium—Shock—Alitretinoin—peripheral nervous system neoplasm	0.000567	0.00133	CcSEcCtD
Lithium—Musculoskeletal discomfort—Dactinomycin—peripheral nervous system neoplasm	0.000566	0.00133	CcSEcCtD
Lithium—Tremor—Cisplatin—peripheral nervous system neoplasm	0.000564	0.00133	CcSEcCtD
Lithium—Alopecia—Etoposide—peripheral nervous system neoplasm	0.00056	0.00132	CcSEcCtD
Lithium—Oedema—Vincristine—peripheral nervous system neoplasm	0.000555	0.00131	CcSEcCtD
Lithium—Asthenia—Topotecan—peripheral nervous system neoplasm	0.00055	0.00129	CcSEcCtD
Lithium—Anorexia—Alitretinoin—peripheral nervous system neoplasm	0.000549	0.00129	CcSEcCtD
Lithium—Asthenia—Tretinoin—peripheral nervous system neoplasm	0.000546	0.00128	CcSEcCtD
Lithium—Asthenia—Isotretinoin—peripheral nervous system neoplasm	0.000546	0.00128	CcSEcCtD
Lithium—Decreased appetite—Dactinomycin—peripheral nervous system neoplasm	0.00054	0.00127	CcSEcCtD
Lithium—Dysgeusia—Etoposide—peripheral nervous system neoplasm	0.00054	0.00127	CcSEcCtD
Lithium—Asthenia—Melphalan—peripheral nervous system neoplasm	0.000539	0.00127	CcSEcCtD
Lithium—Hypotension—Alitretinoin—peripheral nervous system neoplasm	0.000539	0.00127	CcSEcCtD
Lithium—Fatigue—Dactinomycin—peripheral nervous system neoplasm	0.000536	0.00126	CcSEcCtD
Lithium—Anorexia—Vincristine—peripheral nervous system neoplasm	0.000529	0.00125	CcSEcCtD
Lithium—Musculoskeletal discomfort—Alitretinoin—peripheral nervous system neoplasm	0.000525	0.00124	CcSEcCtD
Lithium—Diarrhoea—Topotecan—peripheral nervous system neoplasm	0.000524	0.00123	CcSEcCtD
Lithium—Lethargy—Epirubicin—peripheral nervous system neoplasm	0.000524	0.00123	CcSEcCtD
Lithium—Convulsion—Cisplatin—peripheral nervous system neoplasm	0.000521	0.00123	CcSEcCtD
Lithium—Diarrhoea—Tretinoin—peripheral nervous system neoplasm	0.00052	0.00122	CcSEcCtD
Lithium—Diarrhoea—Isotretinoin—peripheral nervous system neoplasm	0.00052	0.00122	CcSEcCtD
Lithium—Hypotension—Vincristine—peripheral nervous system neoplasm	0.000519	0.00122	CcSEcCtD
Lithium—Diarrhoea—Melphalan—peripheral nervous system neoplasm	0.000514	0.00121	CcSEcCtD
Lithium—Somnolence—Alitretinoin—peripheral nervous system neoplasm	0.000512	0.00121	CcSEcCtD
Lithium—Feeling abnormal—Dactinomycin—peripheral nervous system neoplasm	0.000512	0.00121	CcSEcCtD
Lithium—Gastrointestinal pain—Dactinomycin—peripheral nervous system neoplasm	0.000508	0.0012	CcSEcCtD
Lithium—Dyspepsia—Alitretinoin—peripheral nervous system neoplasm	0.000507	0.00119	CcSEcCtD
Lithium—Dizziness—Topotecan—peripheral nervous system neoplasm	0.000507	0.00119	CcSEcCtD
Lithium—Discomfort—Cisplatin—peripheral nervous system neoplasm	0.000506	0.00119	CcSEcCtD
Lithium—Musculoskeletal discomfort—Vincristine—peripheral nervous system neoplasm	0.000506	0.00119	CcSEcCtD
Lithium—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.000503	0.00118	CcSEcCtD
Lithium—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.000503	0.00118	CcSEcCtD
Lithium—Decreased appetite—Alitretinoin—peripheral nervous system neoplasm	0.000501	0.00118	CcSEcCtD
Lithium—Fatigue—Alitretinoin—peripheral nervous system neoplasm	0.000497	0.00117	CcSEcCtD
Lithium—Vertigo—Etoposide—peripheral nervous system neoplasm	0.000495	0.00117	CcSEcCtD
Lithium—Abdominal pain—Dactinomycin—peripheral nervous system neoplasm	0.000491	0.00116	CcSEcCtD
Lithium—Body temperature increased—Dactinomycin—peripheral nervous system neoplasm	0.000491	0.00116	CcSEcCtD
Lithium—Oedema—Cisplatin—peripheral nervous system neoplasm	0.000491	0.00116	CcSEcCtD
Lithium—Vomiting—Topotecan—peripheral nervous system neoplasm	0.000487	0.00115	CcSEcCtD
Lithium—Loss of consciousness—Etoposide—peripheral nervous system neoplasm	0.000484	0.00114	CcSEcCtD
Lithium—Lethargy—Doxorubicin—peripheral nervous system neoplasm	0.000484	0.00114	CcSEcCtD
Lithium—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.000484	0.00114	CcSEcCtD
Lithium—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.000484	0.00114	CcSEcCtD
Lithium—Rash—Topotecan—peripheral nervous system neoplasm	0.000483	0.00114	CcSEcCtD
Lithium—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.000483	0.00114	CcSEcCtD
Lithium—Decreased appetite—Vincristine—peripheral nervous system neoplasm	0.000483	0.00114	CcSEcCtD
Lithium—Ataxia—Epirubicin—peripheral nervous system neoplasm	0.000482	0.00114	CcSEcCtD
Lithium—Headache—Topotecan—peripheral nervous system neoplasm	0.00048	0.00113	CcSEcCtD
Lithium—Rash—Isotretinoin—peripheral nervous system neoplasm	0.000479	0.00113	CcSEcCtD
Lithium—Rash—Tretinoin—peripheral nervous system neoplasm	0.000479	0.00113	CcSEcCtD
Lithium—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.000479	0.00113	CcSEcCtD
Lithium—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.000479	0.00113	CcSEcCtD
Lithium—Fatigue—Vincristine—peripheral nervous system neoplasm	0.000479	0.00113	CcSEcCtD
Lithium—Convulsion—Etoposide—peripheral nervous system neoplasm	0.000478	0.00112	CcSEcCtD
Lithium—Vomiting—Melphalan—peripheral nervous system neoplasm	0.000477	0.00112	CcSEcCtD
Lithium—Dehydration—Epirubicin—peripheral nervous system neoplasm	0.000477	0.00112	CcSEcCtD
Lithium—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000476	0.00112	CcSEcCtD
Lithium—Headache—Tretinoin—peripheral nervous system neoplasm	0.000476	0.00112	CcSEcCtD
Lithium—Feeling abnormal—Alitretinoin—peripheral nervous system neoplasm	0.000475	0.00112	CcSEcCtD
Lithium—Rash—Melphalan—peripheral nervous system neoplasm	0.000473	0.00111	CcSEcCtD
Lithium—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000473	0.00111	CcSEcCtD
Lithium—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.000471	0.00111	CcSEcCtD
Lithium—Dry skin—Epirubicin—peripheral nervous system neoplasm	0.00047	0.00111	CcSEcCtD
Lithium—Anorexia—Cisplatin—peripheral nervous system neoplasm	0.000468	0.0011	CcSEcCtD
Lithium—Discomfort—Etoposide—peripheral nervous system neoplasm	0.000464	0.00109	CcSEcCtD
Lithium—Hypotension—Cisplatin—peripheral nervous system neoplasm	0.000459	0.00108	CcSEcCtD
Lithium—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.000456	0.00107	CcSEcCtD
Lithium—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.000456	0.00107	CcSEcCtD
Lithium—Nausea—Topotecan—peripheral nervous system neoplasm	0.000455	0.00107	CcSEcCtD
Lithium—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.000454	0.00107	CcSEcCtD
Lithium—Gastritis—Epirubicin—peripheral nervous system neoplasm	0.000454	0.00107	CcSEcCtD
Lithium—Confusional state—Etoposide—peripheral nervous system neoplasm	0.000454	0.00107	CcSEcCtD
Lithium—Muscular weakness—Epirubicin—peripheral nervous system neoplasm	0.000453	0.00107	CcSEcCtD
Lithium—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000452	0.00106	CcSEcCtD
Lithium—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000452	0.00106	CcSEcCtD
Lithium—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.000447	0.00105	CcSEcCtD
Lithium—Ataxia—Doxorubicin—peripheral nervous system neoplasm	0.000446	0.00105	CcSEcCtD
Lithium—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000446	0.00105	CcSEcCtD
Lithium—Nausea—Melphalan—peripheral nervous system neoplasm	0.000446	0.00105	CcSEcCtD
Lithium—Dehydration—Doxorubicin—peripheral nervous system neoplasm	0.000441	0.00104	CcSEcCtD
Lithium—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.000439	0.00103	CcSEcCtD
Lithium—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000439	0.00103	CcSEcCtD
Lithium—Dry skin—Doxorubicin—peripheral nervous system neoplasm	0.000435	0.00102	CcSEcCtD
Lithium—Anorexia—Etoposide—peripheral nervous system neoplasm	0.000429	0.00101	CcSEcCtD
Lithium—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.000427	0.001	CcSEcCtD
Lithium—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000425	0.001	CcSEcCtD
Lithium—Hypotension—Etoposide—peripheral nervous system neoplasm	0.00042	0.000989	CcSEcCtD
Lithium—Gastritis—Doxorubicin—peripheral nervous system neoplasm	0.00042	0.000989	CcSEcCtD
Lithium—Muscular weakness—Doxorubicin—peripheral nervous system neoplasm	0.000419	0.000985	CcSEcCtD
Lithium—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000413	0.000973	CcSEcCtD
Lithium—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.000405	0.000952	CcSEcCtD
Lithium—Weight increased—Epirubicin—peripheral nervous system neoplasm	0.000404	0.00095	CcSEcCtD
Lithium—Weight decreased—Epirubicin—peripheral nervous system neoplasm	0.000401	0.000944	CcSEcCtD
Lithium—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	0.0004	0.000941	CcSEcCtD
Lithium—Somnolence—Etoposide—peripheral nervous system neoplasm	0.0004	0.000941	CcSEcCtD
Lithium—GSK3B—Signaling by FGFR in disease—ERBB2—peripheral nervous system neoplasm	0.0004	0.000832	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—ERBB2—peripheral nervous system neoplasm	0.0004	0.000832	CbGpPWpGaD
Lithium—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000398	0.000938	CcSEcCtD
Lithium—GSK3A—Immune System—PPP3R1—peripheral nervous system neoplasm	0.000397	0.000826	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—ERBB2—peripheral nervous system neoplasm	0.000396	0.000825	CbGpPWpGaD
Lithium—Drowsiness—Epirubicin—peripheral nervous system neoplasm	0.000395	0.000931	CcSEcCtD
Lithium—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000395	0.00093	CcSEcCtD
Lithium—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000394	0.000928	CcSEcCtD
Lithium—GSK3B—Signaling by EGFR in Cancer—ERBB2—peripheral nervous system neoplasm	0.000393	0.000817	CbGpPWpGaD
Lithium—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000392	0.000922	CcSEcCtD
Lithium—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000391	0.00092	CcSEcCtD
Lithium—GSK3B—Signaling by PDGF—ERBB2—peripheral nervous system neoplasm	0.000391	0.000814	CbGpPWpGaD
Lithium—GSK3B—Leptin signaling pathway—AKT1—peripheral nervous system neoplasm	0.000391	0.000813	CbGpPWpGaD
Lithium—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000388	0.000914	CcSEcCtD
Lithium—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000388	0.000913	CcSEcCtD
Lithium—GSK3B—Disease—GNS—peripheral nervous system neoplasm	0.000387	0.000806	CbGpPWpGaD
Lithium—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000381	0.000897	CcSEcCtD
Lithium—GRIA3—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	0.000381	0.000793	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—NRAS—peripheral nervous system neoplasm	0.000381	0.000793	CbGpPWpGaD
Lithium—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.00038	0.000894	CcSEcCtD
Lithium—GSK3B—Focal Adhesion—ERBB2—peripheral nervous system neoplasm	0.000378	0.000786	CbGpPWpGaD
Lithium—Weight increased—Doxorubicin—peripheral nervous system neoplasm	0.000373	0.000879	CcSEcCtD
Lithium—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	0.000371	0.000874	CcSEcCtD
Lithium—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.000371	0.000873	CcSEcCtD
Lithium—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	0.00037	0.000871	CcSEcCtD
Lithium—GSK3B—B Cell Activation—ERBB2—peripheral nervous system neoplasm	0.00037	0.00077	CbGpPWpGaD
Lithium—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000369	0.000869	CcSEcCtD
Lithium—GSK3A—Signaling by NGF—ERBB2—peripheral nervous system neoplasm	0.000369	0.000767	CbGpPWpGaD
Lithium—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000368	0.000866	CcSEcCtD
Lithium—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000367	0.000864	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000367	0.000763	CbGpPWpGaD
Lithium—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000366	0.000862	CcSEcCtD
Lithium—GSK3A—Disease—PPP3R1—peripheral nervous system neoplasm	0.000366	0.000762	CbGpPWpGaD
Lithium—Drowsiness—Doxorubicin—peripheral nervous system neoplasm	0.000366	0.000861	CcSEcCtD
Lithium—GSK3B—Signaling by SCF-KIT—NRAS—peripheral nervous system neoplasm	0.000365	0.000759	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—NRAS—peripheral nervous system neoplasm	0.000365	0.000759	CbGpPWpGaD
Lithium—GSK3B—Glucocorticoid receptor regulatory network—AKT1—peripheral nervous system neoplasm	0.000364	0.000757	CbGpPWpGaD
Lithium—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000363	0.000855	CcSEcCtD
Lithium—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000363	0.000854	CcSEcCtD
Lithium—GSK3B—Wnt Signaling Pathway and Pluripotency—TP53—peripheral nervous system neoplasm	0.000362	0.000753	CbGpPWpGaD
Lithium—GSK3B—Cell Cycle—TP53—peripheral nervous system neoplasm	0.000362	0.000753	CbGpPWpGaD
Lithium—Bradycardia—Epirubicin—peripheral nervous system neoplasm	0.000361	0.00085	CcSEcCtD
Lithium—GSK3A—Signaling by SCF-KIT—HRAS—peripheral nervous system neoplasm	0.000361	0.000752	CbGpPWpGaD
Lithium—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000361	0.00085	CcSEcCtD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	0.000361	0.000751	CbGpPWpGaD
Lithium—GSK3B—B Cell Receptor Signaling Pathway—HRAS—peripheral nervous system neoplasm	0.00036	0.000749	CbGpPWpGaD
Lithium—GSK3A—Integrated Breast Cancer Pathway—TP53—peripheral nervous system neoplasm	0.000358	0.000744	CbGpPWpGaD
Lithium—GSK3B—MicroRNAs in cardiomyocyte hypertrophy—AKT1—peripheral nervous system neoplasm	0.000357	0.000742	CbGpPWpGaD
Lithium—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000356	0.000837	CcSEcCtD
Lithium—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000356	0.000837	CcSEcCtD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—ERBB2—peripheral nervous system neoplasm	0.000354	0.000737	CbGpPWpGaD
Lithium—GSK3B—Senescence and Autophagy in Cancer—TP53—peripheral nervous system neoplasm	0.000353	0.000735	CbGpPWpGaD
Lithium—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000353	0.000831	CcSEcCtD
Lithium—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000352	0.000829	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000352	0.000732	CbGpPWpGaD
Lithium—GSK3A—Immune System—NCAM1—peripheral nervous system neoplasm	0.000351	0.00073	CbGpPWpGaD
Lithium—Rash—Vincristine—peripheral nervous system neoplasm	0.00035	0.000824	CcSEcCtD
Lithium—GSK3B—Constitutive PI3K/AKT Signaling in Cancer—AKT1—peripheral nervous system neoplasm	0.00035	0.000728	CbGpPWpGaD
Lithium—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.00035	0.000823	CcSEcCtD
Lithium—GSK3B—Downstream signaling of activated FGFR—NRAS—peripheral nervous system neoplasm	0.000349	0.000727	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—IFNB1—peripheral nervous system neoplasm	0.000349	0.000726	CbGpPWpGaD
Lithium—Headache—Vincristine—peripheral nervous system neoplasm	0.000348	0.000819	CcSEcCtD
Lithium—GSK3A—Downstream signaling of activated FGFR—HRAS—peripheral nervous system neoplasm	0.000346	0.000719	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—PTPN11—peripheral nervous system neoplasm	0.000345	0.000717	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—NRAS—peripheral nervous system neoplasm	0.000344	0.000715	CbGpPWpGaD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—TP53—peripheral nervous system neoplasm	0.000343	0.000714	CbGpPWpGaD
Lithium—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000342	0.000806	CcSEcCtD
Lithium—GSK3B—Androgen receptor signaling pathway—AKT1—peripheral nervous system neoplasm	0.000341	0.000709	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB4—HRAS—peripheral nervous system neoplasm	0.00034	0.000708	CbGpPWpGaD
Lithium—GSK3B—Senescence and Autophagy in Cancer—HRAS—peripheral nervous system neoplasm	0.000338	0.000703	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—MET—peripheral nervous system neoplasm	0.000337	0.000702	CbGpPWpGaD
Lithium—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000336	0.000791	CcSEcCtD
Lithium—GSK3A—Signaling by NGF—CASP3—peripheral nervous system neoplasm	0.000335	0.000696	CbGpPWpGaD
Lithium—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	0.000334	0.000787	CcSEcCtD
Lithium—GSK3B—Corticotropin-releasing hormone—AKT1—peripheral nervous system neoplasm	0.000332	0.00069	CbGpPWpGaD
Lithium—Tinnitus—Epirubicin—peripheral nervous system neoplasm	0.000331	0.000779	CcSEcCtD
Lithium—Nausea—Vincristine—peripheral nervous system neoplasm	0.00033	0.000776	CcSEcCtD
Lithium—GSK3B—Downstream signal transduction—NRAS—peripheral nervous system neoplasm	0.000328	0.000683	CbGpPWpGaD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—HRAS—peripheral nervous system neoplasm	0.000328	0.000683	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—NRAS—peripheral nervous system neoplasm	0.000326	0.00068	CbGpPWpGaD
Lithium—GSK3A—Insulin Signaling—HRAS—peripheral nervous system neoplasm	0.000326	0.000679	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—NRAS—peripheral nervous system neoplasm	0.000325	0.000676	CbGpPWpGaD
Lithium—GSK3A—Downstream signal transduction—HRAS—peripheral nervous system neoplasm	0.000325	0.000676	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—NRAS—peripheral nervous system neoplasm	0.000323	0.000673	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR—HRAS—peripheral nervous system neoplasm	0.000323	0.000673	CbGpPWpGaD
Lithium—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000323	0.00076	CcSEcCtD
Lithium—GSK3A—Signaling by ERBB2—HRAS—peripheral nervous system neoplasm	0.000322	0.000669	CbGpPWpGaD
Lithium—GSK3A—DAP12 signaling—HRAS—peripheral nervous system neoplasm	0.00032	0.000666	CbGpPWpGaD
Lithium—GSK3A—Signaling by SCF-KIT—AKT1—peripheral nervous system neoplasm	0.000319	0.000664	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—NRAS—peripheral nervous system neoplasm	0.000319	0.000663	CbGpPWpGaD
Lithium—GSK3B—B Cell Receptor Signaling Pathway—AKT1—peripheral nervous system neoplasm	0.000318	0.000662	CbGpPWpGaD
Lithium—GSK3A—Disease—ENO2—peripheral nervous system neoplasm	0.000317	0.000661	CbGpPWpGaD
Lithium—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	0.000317	0.000746	CcSEcCtD
Lithium—GSK3A—Downstream signaling events of B Cell Receptor (BCR)—HRAS—peripheral nervous system neoplasm	0.000315	0.000657	CbGpPWpGaD
Lithium—GSK3B—PI-3K cascade—AKT1—peripheral nervous system neoplasm	0.000315	0.000656	CbGpPWpGaD
Lithium—Alopecia—Epirubicin—peripheral nervous system neoplasm	0.000314	0.000738	CcSEcCtD
Lithium—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000312	0.000735	CcSEcCtD
Lithium—GSK3B—Axon guidance—PTPN11—peripheral nervous system neoplasm	0.000312	0.000649	CbGpPWpGaD
Lithium—Rash—Cisplatin—peripheral nervous system neoplasm	0.00031	0.000729	CcSEcCtD
Lithium—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000309	0.000728	CcSEcCtD
Lithium—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000308	0.000724	CcSEcCtD
Lithium—GSK3B—PI3K/AKT activation—AKT1—peripheral nervous system neoplasm	0.000308	0.000641	CbGpPWpGaD
Lithium—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	0.000306	0.000721	CcSEcCtD
Lithium—GSK3B—GAB1 signalosome—AKT1—peripheral nervous system neoplasm	0.000305	0.000636	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling of activated FGFR—AKT1—peripheral nervous system neoplasm	0.000305	0.000635	CbGpPWpGaD
Lithium—GSK3B—Immune System—CD34—peripheral nervous system neoplasm	0.000305	0.000634	CbGpPWpGaD
Lithium—Flatulence—Epirubicin—peripheral nervous system neoplasm	0.000304	0.000717	CcSEcCtD
Lithium—GSK3B—Signaling by FGFR in disease—NRAS—peripheral nervous system neoplasm	0.000304	0.000633	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—NRAS—peripheral nervous system neoplasm	0.000304	0.000633	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—NRAS—peripheral nervous system neoplasm	0.000304	0.000633	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—CDKN2A—peripheral nervous system neoplasm	0.000304	0.000632	CbGpPWpGaD
Lithium—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	0.000303	0.000712	CcSEcCtD
Lithium—GSK3A—Integrated Breast Cancer Pathway—AKT1—peripheral nervous system neoplasm	0.000302	0.000628	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—NRAS—peripheral nervous system neoplasm	0.000301	0.000627	CbGpPWpGaD
Lithium—GSK3A—DAP12 interactions—HRAS—peripheral nervous system neoplasm	0.000301	0.000627	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—HRAS—peripheral nervous system neoplasm	0.000301	0.000627	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—HRAS—peripheral nervous system neoplasm	0.000301	0.000627	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB4—AKT1—peripheral nervous system neoplasm	0.0003	0.000625	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—NRAS—peripheral nervous system neoplasm	0.000299	0.000622	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR—HRAS—peripheral nervous system neoplasm	0.000298	0.000621	CbGpPWpGaD
Lithium—GSK3B—Role of LAT2/NTAL/LAB on calcium mobilization—AKT1—peripheral nervous system neoplasm	0.000298	0.000621	CbGpPWpGaD
Lithium—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000297	0.0007	CcSEcCtD
Lithium—GSK3B—Signaling by PDGF—NRAS—peripheral nervous system neoplasm	0.000297	0.000619	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	0.000296	0.000617	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR in Cancer—HRAS—peripheral nervous system neoplasm	0.000296	0.000616	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—HRAS—peripheral nervous system neoplasm	0.000294	0.000613	CbGpPWpGaD
Lithium—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	0.000293	0.000691	CcSEcCtD
Lithium—GSK3B—Immune System—PPP3R1—peripheral nervous system neoplasm	0.000293	0.00061	CbGpPWpGaD
Lithium—GRIA3—Neuronal System—HRAS—peripheral nervous system neoplasm	0.000292	0.000608	CbGpPWpGaD
Lithium—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000292	0.000686	CcSEcCtD
Lithium—Vision blurred—Epirubicin—peripheral nervous system neoplasm	0.000291	0.000685	CcSEcCtD
Lithium—Alopecia—Doxorubicin—peripheral nervous system neoplasm	0.00029	0.000683	CcSEcCtD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—AKT1—peripheral nervous system neoplasm	0.00029	0.000603	CbGpPWpGaD
Lithium—GSK3A—Insulin Signaling—AKT1—peripheral nervous system neoplasm	0.000288	0.0006	CbGpPWpGaD
Lithium—GSK3A—Downstream signal transduction—AKT1—peripheral nervous system neoplasm	0.000287	0.000597	CbGpPWpGaD
Lithium—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000286	0.000673	CcSEcCtD
Lithium—GSK3A—Signaling by FGFR—AKT1—peripheral nervous system neoplasm	0.000285	0.000594	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB2—AKT1—peripheral nervous system neoplasm	0.000284	0.000591	CbGpPWpGaD
Lithium—Agitation—Epirubicin—peripheral nervous system neoplasm	0.000284	0.000668	CcSEcCtD
Lithium—Rash—Etoposide—peripheral nervous system neoplasm	0.000284	0.000668	CcSEcCtD
Lithium—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000283	0.000667	CcSEcCtD
Lithium—GSK3A—DAP12 signaling—AKT1—peripheral nervous system neoplasm	0.000283	0.000588	CbGpPWpGaD
Lithium—Headache—Etoposide—peripheral nervous system neoplasm	0.000282	0.000663	CcSEcCtD
Lithium—Flatulence—Doxorubicin—peripheral nervous system neoplasm	0.000282	0.000663	CcSEcCtD
Lithium—GSK3B—B Cell Activation—NRAS—peripheral nervous system neoplasm	0.000281	0.000586	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—NRAS—peripheral nervous system neoplasm	0.00028	0.000584	CbGpPWpGaD
Lithium—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	0.00028	0.000659	CcSEcCtD
Lithium—GSK3A—B Cell Activation—HRAS—peripheral nervous system neoplasm	0.000279	0.00058	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling events of B Cell Receptor (BCR)—AKT1—peripheral nervous system neoplasm	0.000279	0.00058	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000278	0.000579	CbGpPWpGaD
Lithium—Vertigo—Epirubicin—peripheral nervous system neoplasm	0.000278	0.000653	CcSEcCtD
Lithium—Syncope—Epirubicin—peripheral nervous system neoplasm	0.000277	0.000652	CcSEcCtD
Lithium—GSK3A—Immune System—IFNB1—peripheral nervous system neoplasm	0.000275	0.000572	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—ERBB2—peripheral nervous system neoplasm	0.000272	0.000567	CbGpPWpGaD
Lithium—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	0.000272	0.000639	CcSEcCtD
Lithium—GSK3B—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000271	0.000564	CbGpPWpGaD
Lithium—GSK3B—Disease—PPP3R1—peripheral nervous system neoplasm	0.000271	0.000563	CbGpPWpGaD
Lithium—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	0.000269	0.000634	CcSEcCtD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—NRAS—peripheral nervous system neoplasm	0.000269	0.000561	CbGpPWpGaD
Lithium—Convulsion—Epirubicin—peripheral nervous system neoplasm	0.000268	0.00063	CcSEcCtD
Lithium—Nausea—Etoposide—peripheral nervous system neoplasm	0.000267	0.000629	CcSEcCtD
Lithium—GSK3B—Signaling by SCF-KIT—HRAS—peripheral nervous system neoplasm	0.000267	0.000556	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—HRAS—peripheral nervous system neoplasm	0.000267	0.000555	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—PTPN11—peripheral nervous system neoplasm	0.000266	0.000554	CbGpPWpGaD
Lithium—GSK3A—DAP12 interactions—AKT1—peripheral nervous system neoplasm	0.000266	0.000553	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—AKT1—peripheral nervous system neoplasm	0.000266	0.000553	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—AKT1—peripheral nervous system neoplasm	0.000266	0.000553	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR—AKT1—peripheral nervous system neoplasm	0.000264	0.000548	CbGpPWpGaD
Lithium—Arthralgia—Epirubicin—peripheral nervous system neoplasm	0.000263	0.000619	CcSEcCtD
Lithium—Agitation—Doxorubicin—peripheral nervous system neoplasm	0.000263	0.000618	CcSEcCtD
Lithium—GSK3B—BDNF signaling pathway—HRAS—peripheral nervous system neoplasm	0.000262	0.000546	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR in Cancer—AKT1—peripheral nervous system neoplasm	0.000261	0.000544	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—AKT1—peripheral nervous system neoplasm	0.00026	0.000541	CbGpPWpGaD
Lithium—Discomfort—Epirubicin—peripheral nervous system neoplasm	0.00026	0.000612	CcSEcCtD
Lithium—GSK3B—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.00026	0.000541	CbGpPWpGaD
Lithium—GSK3B—Immune System—NCAM1—peripheral nervous system neoplasm	0.000259	0.000539	CbGpPWpGaD
Lithium—Dry mouth—Epirubicin—peripheral nervous system neoplasm	0.000257	0.000605	CcSEcCtD
Lithium—Vertigo—Doxorubicin—peripheral nervous system neoplasm	0.000257	0.000605	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000257	0.000534	CbGpPWpGaD
Lithium—Syncope—Doxorubicin—peripheral nervous system neoplasm	0.000256	0.000603	CcSEcCtD
Lithium—GSK3A—Disease—SLC2A1—peripheral nervous system neoplasm	0.000256	0.000532	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—PTPN11—peripheral nervous system neoplasm	0.000255	0.000532	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—HRAS—peripheral nervous system neoplasm	0.000255	0.000532	CbGpPWpGaD
Lithium—Confusional state—Epirubicin—peripheral nervous system neoplasm	0.000254	0.000598	CcSEcCtD
Lithium—Oedema—Epirubicin—peripheral nervous system neoplasm	0.000252	0.000594	CcSEcCtD
Lithium—GSK3B—Signaling by ERBB4—HRAS—peripheral nervous system neoplasm	0.000251	0.000523	CbGpPWpGaD
Lithium—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	0.000251	0.000591	CcSEcCtD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	0.00025	0.000521	CbGpPWpGaD
Lithium—Shock—Epirubicin—peripheral nervous system neoplasm	0.000248	0.000584	CcSEcCtD
Lithium—Convulsion—Doxorubicin—peripheral nervous system neoplasm	0.000248	0.000583	CcSEcCtD
Lithium—GSK3B—Signaling by NGF—CASP3—peripheral nervous system neoplasm	0.000247	0.000514	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—ERBB2—peripheral nervous system neoplasm	0.000246	0.000513	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—AKT1—peripheral nervous system neoplasm	0.000246	0.000512	CbGpPWpGaD
Lithium—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	0.000243	0.000573	CcSEcCtD
Lithium—GSK3B—Insulin Signaling—HRAS—peripheral nervous system neoplasm	0.000241	0.000502	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—MET—peripheral nervous system neoplasm	0.000241	0.000501	CbGpPWpGaD
Lithium—Discomfort—Doxorubicin—peripheral nervous system neoplasm	0.00024	0.000566	CcSEcCtD
Lithium—Anorexia—Epirubicin—peripheral nervous system neoplasm	0.00024	0.000566	CcSEcCtD
Lithium—GSK3B—Downstream signal transduction—HRAS—peripheral nervous system neoplasm	0.00024	0.0005	CbGpPWpGaD
Lithium—GSK3B—TCF dependent signaling in response to WNT—MYC—peripheral nervous system neoplasm	0.00024	0.000499	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—HRAS—peripheral nervous system neoplasm	0.000239	0.000497	CbGpPWpGaD
Lithium—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	0.000238	0.00056	CcSEcCtD
Lithium—GSK3B—Signaling by ERBB2—HRAS—peripheral nervous system neoplasm	0.000238	0.000495	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—HRAS—peripheral nervous system neoplasm	0.000237	0.000492	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—AKT1—peripheral nervous system neoplasm	0.000236	0.000491	CbGpPWpGaD
Lithium—Hypotension—Epirubicin—peripheral nervous system neoplasm	0.000236	0.000555	CcSEcCtD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—AKT1—peripheral nervous system neoplasm	0.000235	0.00049	CbGpPWpGaD
Lithium—Confusional state—Doxorubicin—peripheral nervous system neoplasm	0.000235	0.000554	CcSEcCtD
Lithium—GSK3B—Disease—ENO2—peripheral nervous system neoplasm	0.000235	0.000488	CbGpPWpGaD
Lithium—Oedema—Doxorubicin—peripheral nervous system neoplasm	0.000233	0.000549	CcSEcCtD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—HRAS—peripheral nervous system neoplasm	0.000233	0.000485	CbGpPWpGaD
Lithium—GSK3B—RNF mutants show enhanced WNT signaling and proliferation—MYC—peripheral nervous system neoplasm	0.000232	0.000483	CbGpPWpGaD
Lithium—GSK3B—BDNF signaling pathway—AKT1—peripheral nervous system neoplasm	0.000232	0.000482	CbGpPWpGaD
Lithium—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	0.00023	0.000541	CcSEcCtD
Lithium—Shock—Doxorubicin—peripheral nervous system neoplasm	0.00023	0.00054	CcSEcCtD
Lithium—GSK3B—Downstream signaling of activated FGFR—AKT1—peripheral nervous system neoplasm	0.000225	0.000469	CbGpPWpGaD
Lithium—Somnolence—Epirubicin—peripheral nervous system neoplasm	0.000224	0.000528	CcSEcCtD
Lithium—GSK3B—Developmental Biology—PTPN11—peripheral nervous system neoplasm	0.000223	0.000463	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—HRAS—peripheral nervous system neoplasm	0.000223	0.000463	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—HRAS—peripheral nervous system neoplasm	0.000223	0.000463	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—HRAS—peripheral nervous system neoplasm	0.000223	0.000463	CbGpPWpGaD
Lithium—Anorexia—Doxorubicin—peripheral nervous system neoplasm	0.000222	0.000523	CcSEcCtD
Lithium—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	0.000222	0.000522	CcSEcCtD
Lithium—GSK3B—Signaling by ERBB4—AKT1—peripheral nervous system neoplasm	0.000222	0.000462	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—HRAS—peripheral nervous system neoplasm	0.000221	0.000459	CbGpPWpGaD
Lithium—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	0.000219	0.000516	CcSEcCtD
Lithium—GSK3B—Signaling by EGFR in Cancer—HRAS—peripheral nervous system neoplasm	0.000219	0.000455	CbGpPWpGaD
Lithium—Hypotension—Doxorubicin—peripheral nervous system neoplasm	0.000218	0.000513	CcSEcCtD
Lithium—GSK3B—Signaling by PDGF—HRAS—peripheral nervous system neoplasm	0.000218	0.000453	CbGpPWpGaD
Lithium—Fatigue—Epirubicin—peripheral nervous system neoplasm	0.000217	0.000512	CcSEcCtD
Lithium—GSK3B—Signaling by WNT in cancer—MYC—peripheral nervous system neoplasm	0.000216	0.000449	CbGpPWpGaD
Lithium—GSK3B—Insulin Signaling—AKT1—peripheral nervous system neoplasm	0.000213	0.000443	CbGpPWpGaD
Lithium—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000213	0.0005	CcSEcCtD
Lithium—GSK3A—Immune System—HGF—peripheral nervous system neoplasm	0.000212	0.000442	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—AKT1—peripheral nervous system neoplasm	0.000212	0.000441	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—AKT1—peripheral nervous system neoplasm	0.000211	0.000439	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—HRAS—peripheral nervous system neoplasm	0.00021	0.000438	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—ERBB2—peripheral nervous system neoplasm	0.00021	0.000438	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	0.00021	0.000437	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—AKT1—peripheral nervous system neoplasm	0.00021	0.000437	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—AKT1—peripheral nervous system neoplasm	0.000209	0.000435	CbGpPWpGaD
Lithium—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	0.000208	0.000489	CcSEcCtD
Lithium—Somnolence—Doxorubicin—peripheral nervous system neoplasm	0.000207	0.000488	CcSEcCtD
Lithium—GSK3B—Signaling by NGF—NRAS—peripheral nervous system neoplasm	0.000207	0.000431	CbGpPWpGaD
Lithium—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	0.000206	0.000485	CcSEcCtD
Lithium—GSK3B—B Cell Activation—HRAS—peripheral nervous system neoplasm	0.000206	0.000429	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—AKT1—peripheral nervous system neoplasm	0.000206	0.000428	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000205	0.000428	CbGpPWpGaD
Lithium—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	0.000205	0.000483	CcSEcCtD
Lithium—GSK3A—Signaling by NGF—HRAS—peripheral nervous system neoplasm	0.000205	0.000427	CbGpPWpGaD
Lithium—GSK3B—Immune System—IFNB1—peripheral nervous system neoplasm	0.000203	0.000423	CbGpPWpGaD
Lithium—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	0.000203	0.000477	CcSEcCtD
Lithium—GSK3A—Adaptive Immune System—ERBB2—peripheral nervous system neoplasm	0.000202	0.00042	CbGpPWpGaD
Lithium—Fatigue—Doxorubicin—peripheral nervous system neoplasm	0.000201	0.000473	CcSEcCtD
Lithium—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	0.000199	0.000469	CcSEcCtD
Lithium—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	0.000199	0.000469	CcSEcCtD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—HRAS—peripheral nervous system neoplasm	0.000197	0.00041	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—PTPN11—peripheral nervous system neoplasm	0.000197	0.000409	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—AKT1—peripheral nervous system neoplasm	0.000196	0.000409	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—AKT1—peripheral nervous system neoplasm	0.000196	0.000409	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—AKT1—peripheral nervous system neoplasm	0.000196	0.000409	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—AKT1—peripheral nervous system neoplasm	0.000195	0.000405	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—AKT1—peripheral nervous system neoplasm	0.000193	0.000402	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.000193	0.000401	CbGpPWpGaD
Lithium—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	0.000192	0.000453	CcSEcCtD
Lithium—GSK3B—Signaling by PDGF—AKT1—peripheral nervous system neoplasm	0.000192	0.0004	CbGpPWpGaD
Lithium—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	0.000191	0.000449	CcSEcCtD
Lithium—GSK3B—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.00019	0.000395	CbGpPWpGaD
Lithium—GSK3B—Disease—SLC2A1—peripheral nervous system neoplasm	0.000189	0.000393	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—PTPN11—peripheral nervous system neoplasm	0.000189	0.000393	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—NRAS—peripheral nervous system neoplasm	0.000188	0.00039	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—AKT1—peripheral nervous system neoplasm	0.000186	0.000386	CbGpPWpGaD
Lithium—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	0.000184	0.000434	CcSEcCtD
Lithium—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	0.000184	0.000434	CcSEcCtD
Lithium—GSK3B—B Cell Activation—AKT1—peripheral nervous system neoplasm	0.000182	0.000378	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—AKT1—peripheral nervous system neoplasm	0.000181	0.000377	CbGpPWpGaD
Lithium—Asthenia—Epirubicin—peripheral nervous system neoplasm	0.000181	0.000426	CcSEcCtD
Lithium—GSK3B—Signaling by Wnt—MYC—peripheral nervous system neoplasm	0.000178	0.00037	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—ERBB2—peripheral nervous system neoplasm	0.000176	0.000366	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—AKT1—peripheral nervous system neoplasm	0.000174	0.000362	CbGpPWpGaD
Lithium—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.000173	0.000406	CcSEcCtD
Lithium—GSK3B—Cellular responses to stress—TP53—peripheral nervous system neoplasm	0.000169	0.000352	CbGpPWpGaD
Lithium—Asthenia—Doxorubicin—peripheral nervous system neoplasm	0.000167	0.000394	CcSEcCtD
Lithium—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000167	0.000392	CcSEcCtD
Lithium—GSK3B—TCF dependent signaling in response to WNT—AKT1—peripheral nervous system neoplasm	0.000166	0.000346	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—KNG1—peripheral nervous system neoplasm	0.000165	0.000343	CbGpPWpGaD
Lithium—GSK3B—RNF mutants show enhanced WNT signaling and proliferation—AKT1—peripheral nervous system neoplasm	0.000161	0.000335	CbGpPWpGaD
Lithium—Vomiting—Epirubicin—peripheral nervous system neoplasm	0.00016	0.000377	CcSEcCtD
Lithium—GSK3A—Innate Immune System—NRAS—peripheral nervous system neoplasm	0.00016	0.000333	CbGpPWpGaD
Lithium—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	0.00016	0.000376	CcSEcCtD
Lithium—Rash—Epirubicin—peripheral nervous system neoplasm	0.000159	0.000374	CcSEcCtD
Lithium—Dermatitis—Epirubicin—peripheral nervous system neoplasm	0.000159	0.000374	CcSEcCtD
Lithium—Headache—Epirubicin—peripheral nervous system neoplasm	0.000158	0.000372	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	0.000157	0.000327	CbGpPWpGaD
Lithium—GSK3B—Immune System—HGF—peripheral nervous system neoplasm	0.000157	0.000327	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—ERBB2—peripheral nervous system neoplasm	0.000155	0.000323	CbGpPWpGaD
Lithium—GSK3A—Immune System—PTPN11—peripheral nervous system neoplasm	0.000155	0.000322	CbGpPWpGaD
Lithium—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.000154	0.000363	CcSEcCtD
Lithium—GSK3A—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	0.000154	0.00032	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—HRAS—peripheral nervous system neoplasm	0.000152	0.000315	CbGpPWpGaD
Lithium—Nausea—Epirubicin—peripheral nervous system neoplasm	0.00015	0.000353	CcSEcCtD
Lithium—GSK3B—Signaling by WNT in cancer—AKT1—peripheral nervous system neoplasm	0.00015	0.000311	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—ERBB2—peripheral nervous system neoplasm	0.000149	0.00031	CbGpPWpGaD
Lithium—Vomiting—Doxorubicin—peripheral nervous system neoplasm	0.000148	0.000349	CcSEcCtD
Lithium—Rash—Doxorubicin—peripheral nervous system neoplasm	0.000147	0.000346	CcSEcCtD
Lithium—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	0.000147	0.000346	CcSEcCtD
Lithium—Headache—Doxorubicin—peripheral nervous system neoplasm	0.000146	0.000344	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	0.000144	0.0003	CbGpPWpGaD
Lithium—GSK3A—Disease—PTPN11—peripheral nervous system neoplasm	0.000143	0.000298	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.000142	0.000296	CbGpPWpGaD
Lithium—IMPA2—Metabolism—AKT1—peripheral nervous system neoplasm	0.000139	0.000289	CbGpPWpGaD
Lithium—Nausea—Doxorubicin—peripheral nervous system neoplasm	0.000139	0.000326	CcSEcCtD
Lithium—GSK3B—Axon guidance—HRAS—peripheral nervous system neoplasm	0.000137	0.000286	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—AKT1—peripheral nervous system neoplasm	0.000134	0.000279	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—NRAS—peripheral nervous system neoplasm	0.000134	0.000279	CbGpPWpGaD
Lithium—IMPA1—Metabolism—AKT1—peripheral nervous system neoplasm	0.000124	0.000257	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—AKT1—peripheral nervous system neoplasm	0.000123	0.000257	CbGpPWpGaD
Lithium—GSK3A—Immune System—ERBB2—peripheral nervous system neoplasm	0.000122	0.000255	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—KNG1—peripheral nervous system neoplasm	0.000122	0.000253	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—NRAS—peripheral nervous system neoplasm	0.000118	0.000246	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—HRAS—peripheral nervous system neoplasm	0.000117	0.000244	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	0.000116	0.000242	CbGpPWpGaD
Lithium—GSK3B—Immune System—PTPN11—peripheral nervous system neoplasm	0.000114	0.000238	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	0.000113	0.000236	CbGpPWpGaD
Lithium—GSK3A—Disease—ERBB2—peripheral nervous system neoplasm	0.000113	0.000235	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	0.000112	0.000234	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—GNAS—peripheral nervous system neoplasm	0.000107	0.000222	CbGpPWpGaD
Lithium—GSK3B—Disease—PTPN11—peripheral nervous system neoplasm	0.000106	0.00022	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—AKT1—peripheral nervous system neoplasm	0.000103	0.000215	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	0.0001	0.000208	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	9.92e-05	0.000206	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—HRAS—peripheral nervous system neoplasm	9.79e-05	0.000204	CbGpPWpGaD
Lithium—GSK3A—Immune System—NRAS—peripheral nervous system neoplasm	9.31e-05	0.000194	CbGpPWpGaD
Lithium—GSK3B—Immune System—ERBB2—peripheral nervous system neoplasm	9.05e-05	0.000188	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—HRAS—peripheral nervous system neoplasm	8.65e-05	0.00018	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—AKT1—peripheral nervous system neoplasm	8.64e-05	0.00018	CbGpPWpGaD
Lithium—GSK3A—Disease—NRAS—peripheral nervous system neoplasm	8.6e-05	0.000179	CbGpPWpGaD
Lithium—GSK3B—Disease—ERBB2—peripheral nervous system neoplasm	8.35e-05	0.000174	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	8.3e-05	0.000173	CbGpPWpGaD
Lithium—GSK3A—Disease—MYC—peripheral nervous system neoplasm	8.01e-05	0.000167	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	7.92e-05	0.000165	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—AKT1—peripheral nervous system neoplasm	7.63e-05	0.000159	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	7.4e-05	0.000154	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	7.33e-05	0.000153	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	7.19e-05	0.00015	CbGpPWpGaD
Lithium—GSK3B—Immune System—NRAS—peripheral nervous system neoplasm	6.88e-05	0.000143	CbGpPWpGaD
Lithium—GSK3A—Immune System—HRAS—peripheral nervous system neoplasm	6.81e-05	0.000142	CbGpPWpGaD
Lithium—GSK3B—Disease—NRAS—peripheral nervous system neoplasm	6.36e-05	0.000132	CbGpPWpGaD
Lithium—GSK3A—Disease—HRAS—peripheral nervous system neoplasm	6.29e-05	0.000131	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	6.02e-05	0.000125	CbGpPWpGaD
Lithium—GSK3A—Immune System—AKT1—peripheral nervous system neoplasm	6.02e-05	0.000125	CbGpPWpGaD
Lithium—GSK3B—Disease—MYC—peripheral nervous system neoplasm	5.92e-05	0.000123	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.85e-05	0.000122	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MYC—peripheral nervous system neoplasm	5.61e-05	0.000117	CbGpPWpGaD
Lithium—GSK3A—Disease—AKT1—peripheral nervous system neoplasm	5.56e-05	0.000116	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.31e-05	0.000111	CbGpPWpGaD
Lithium—GSK3B—Immune System—HRAS—peripheral nervous system neoplasm	5.04e-05	0.000105	CbGpPWpGaD
Lithium—GSK3B—Disease—HRAS—peripheral nervous system neoplasm	4.65e-05	9.68e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.61e-05	9.59e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.45e-05	9.26e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—AKT1—peripheral nervous system neoplasm	4.45e-05	9.25e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.41e-05	9.17e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.15e-05	8.63e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—AKT1—peripheral nervous system neoplasm	4.11e-05	8.54e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.89e-05	8.1e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.4e-05	7.09e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.26e-05	6.78e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.87e-05	5.98e-05	CbGpPWpGaD
